

All you need to know about the delisting from Nasdaq First North

1. Why is Onxeo delisting from Nasdaq First North?

The dual listing of shares, in France and in Denmark, is the legacy of the merger between the French company BioAlliance Pharma SA and the Danish company Topotarget in 2014, which gave birth to Onxeo. After several years of development of Beleodaq, a product from Topotarget, the Company has completely outsourced this product and no longer has operational links with Denmark today. In parallel, it has refocused on the field of targeting tumor DNA damage response (DDR) mechanisms, with promising drug candidates at an earlier stage of development. In this context, Onxeo is striving to simplify its operational processes and minimize its fixed costs, and the abolition of the secondary listing in Denmark is a clear step in this direction

2. What are the benefits of this delisting from the Danish stock market for Onxeo and its shareholders?

In addition to a considerable reduction in costs, a simple listing in Paris presents several advantages for Onxeo and its shareholders, as the Euronext Growth market:

- is considered the leading European stock market for healthcare and biotechnology SMEs;
- provides a legal and regulatory framework that meets the highest standards of protection and transparency to investors;
- offers a higher level of liquidity.

3. What does it mean to “delist” the Company from Nasdaq First North?

It is the process by which Onxeo is removed from the market of the Nasdaq First North Copenhagen. This means that if you hold shares of Onxeo after its delisting, you will no longer be able to trade them on this market. Your shares will be automatically transferred to Euronext Growth in Paris. Following this purely technical operation, Danish shareholders will be able to freely trade Onxeo shares on Euronext Growth. The ISIN code (FR0010095596) remains the same and the ticker code (ALONX) will follow the nomenclature of the Euronext Growth market.

4. Will the number of ordinary shares be modified following the transfer?

No changes will be made to the number of ordinary shares or the rights attached to the Onxeo shares and the Company's share capital will thus remain unchanged.

5. When will Onxeo be officially delisted from Nasdaq First North?

Subject to shareholders' approval during the Combined General Meeting on August 17, 2022, the application to delist Onxeo's shares will be filed with Nasdaq First North Copenhagen. After approval by the market operator, on average within ten days, the effective transfer of shares from the Nasdaq First North market to the Euronext Growth market will take place after an additional period of 10 weeks.

**6. Which options do I have as a shareholder?**

You will be able to:

- Keep your shares: in this case, simply do nothing; your shares will be transferred to Euronext Growth Paris and your rights will remain unchanged.
- Buy or sell Onxeo shares in the usual manner up to the last trading day on Nasdaq First North, which will be announced in due time. The number of Onxeo shares you will own at this date will simply be transferred to Euronext Growth.

7. What do I have to do to transfer my shares from Nasdaq First North to Euronext Growth Paris?

Nothing is required. The transfer will occur automatically.

8. Should I expect to pay fees when trading on Euronext Growth Paris?

Trading fees will be payable to your bank when buying and selling Onxeo shares on Euronext Growth and you should ask your bank to provide details about it.

Additionally, as the shares will be tradable in Euros, Danish shareholders will potentially have to pay the exchange rate costs related to the conversion of the Euro (EUR) into Danish Kroner (DKK), the parity of which is historically stable.

9. Where can I follow the daily change in stock price after the transfer?

You can follow the Onxeo's stock price evolution on the Euronext Growth live markets website:

<https://live.euronext.com/en/product/equities/FR0010095596-ALXP>

10. Should we expect a complete delisting of Onxeo in the near future?

No, there are no plans for Onxeo to delist from Euronext Growth.

11. Who can I speak to if I have others questions regarding the delisting?

You can contact us by e-mail at investors@onxeo.com and onxeo@newcap.eu or by phone at +33 1 44 71 94 92.